Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01946035
Other study ID # 2012RC14
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 2013
Est. completion date June 2015

Study information

Verified date April 2019
Source University of Dundee
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Allergic rhinitis (allergic inflammation of the nose) is a common medical condition which is known to seriously decrease quality of life, aggravate preexisting conditions particularly asthma, carry significant medical treatment costs and be responsible for reduced work productivity and lost school days. A significant symptom of the condition, nasal blockage, remains difficult to treat even when using nasal corticosteroids. Decongestant medications act on the blood vessels in the nose and have an immediate effect in clearing a blocked nose but if used for more than seven days a more severe rebound congestion of the nose develops.

In this study, the investigators aim to assess the effects of doxazosin, a drug which is currently used to treat high blood pressure and symptoms of prostate enlargement, to find out if it has an effect on nasal blockage.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Male or female 18-70 years

- Able to provide informed consent

- Able to comply with the requirements of the protocol

- Diagnosis of allergic rhinitis

- Peak nasal inspiratory flow which is reversible to >20 l/min with oxymetazoline

- Positive skin prick test to at least one common aeroallergen

- Ability to withhold antihistamines, intranasal corticosteroids for duration of the study

- Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant's well being

Exclusion Criteria:

- Pregnancy, planned pregnancy or lactation

- Respiratory tract infection in the previous 2 months

- Nasal polyps of more than Grade I on nasal endoscopy

- Any known adverse reaction to the Investigational Medicinal Product or other quinazolines

- Systolic BP <100mmHg

- Any degree of heart block

- Any clinically significant medical condition that may endanger the health or safety of the participant or jeopardise the protocol

- Participation within another clinical trial of investigational medicinal product within the last 30 days

- Under the age of 18

- Benign hyperplasia, chronic urinary tract infections, bladder stones, overflow bladder, anuria or progressive renal failure

- History of oesophageal or gastrointestinal obstruction or decreased lumen diameter of the gastrointestinal tract.

- Concomitant use of PDE5 inhibitors (sildenafil etc.)

- Alpha antagonists - this is the medication under investigation.

- Other cardiovascular medications including but not limited to:

ACE inhibitors, Angiotensin II antagonists, Beta blockers, calcium channel blockers, diuretics, nitrates, phosphodiesterase type-5 inhibitors or other vasodilating medications - these in combination with doxazosin carry an increased risk of symptomatic hypotension.

- Monoamine oxidase inhibitors (MAOIs) - antidepressant medication that can lead to significant hypotension in combination with alpha antagonists.

- Anxiolytics and hypnotics - enhanced hypotensive and sedative effects when alpha-blockers given in combination with these.

- Methyldopa and levodopa - potential enhanced hypotensive effect with alpha antagonists.

- Nasal corticosteroid spray - would confound study outcomes

- Oxymetazoline - this is used as an outcome of response in the study.

- Antihistamines - the participants will be undergoing a histamine nasal challenge.

- Sympathomimetics i.e. dopamine, ephedrine, epinephrine, metaraminol, methoxamine, phenylephrine- may reduce the effect of doxazosin.

- Any other medication, which in the opinion of the Investigator may put the participant at risk.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doxazosin XL

Other:
Placebo


Locations

Country Name City State
United Kingdom Brian Lipworth Dundee

Sponsors (1)

Lead Sponsor Collaborator
University of Dundee

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Manoharan A, Morrison AE, Lipworth BJ. Effects of the inverse alpha-agonist doxazosin in allergic rhinitis. Clin Exp Allergy. 2016 May;46(5):696-704. doi: 10.1111/cea.12700. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in peak nasal inspiratory from baseline as compared with acute and chronic dosing of doxazosin versus placebo 12 hours; 3 to 5 weeks
Secondary Nasal histamine challenge response as measured by peak nasal inspiratory flow after chronic dosing 12 hours; 3 to 5 weeks
Secondary Nasal airways resistance after single and chronic dosing 12 hours; 3 to 5 weeks
Secondary Domiciliary peak nasal inspiratory measurements after chronic dosing 12 hours; 3 to 5 weeks
Secondary Symptoms after chronic dosing 12 hours; 3 to 5 weeks
Secondary Mini Rhinoconjunctivitis Quality of Life Questionnaire after chronic dosing 24 hours; 3 to 5 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05080322 - Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis Phase 4
Recruiting NCT06028490 - A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis. Phase 2
Completed NCT04388358 - Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation N/A
Recruiting NCT04202263 - Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline Phase 2
Completed NCT04078009 - Standardising Nasal Allergen Challenge in Adult With Hay Fever N/A
Completed NCT03644680 - Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study N/A
Completed NCT04541004 - Adolescent Mite Allergy Safety Evaluation Phase 3
Recruiting NCT05378594 - HDM and Silver Birch NAC Standardisation N/A
Not yet recruiting NCT05684380 - Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) Phase 3
Not yet recruiting NCT01014325 - Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy Phase 3
Completed NCT02943720 - ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen Phase 2
Completed NCT02910401 - Clinical Response to Rhinovirus Challenge Phase 2
Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2
Not yet recruiting NCT02233426 - Effect of Hypertonic Solutions on Allergic Rhinitis Patients N/A
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Recruiting NCT01454492 - The Relationship Between Allergic Rhinitis and Geographic Tongue N/A
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2
Completed NCT01439815 - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Phase 4